

CORRIGENDUM



Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q’

[Annals of Oncology 30 (2019) 1821–1830]

K. L. Jhaveri^{1*}, X. V. Wang², V. Makker³, S.-W. Luoh⁴, E. P. Mitchell⁵, J. A. Zwiebel⁶, E. Sharon⁷, R. J. Gray⁸, S. Li⁸, L. M. McShane⁹, L. V. Rubinstein¹⁰, D. Patton¹¹, P. M. Williams¹², S. R. Hamilton¹³, B. A. Conley¹⁴, C. L. Arteaga¹⁵, L. N. Harris¹⁴, P. J. O’Dwyer¹⁶, A. P. Chen¹⁷ & K. T. Flaherty¹⁸

¹Department of Medicine, Memorial Sloan-Kettering Center, New York; ²Biostatistics, E-A Biostatistical Center, Boston; ³Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, New York; ⁴Knight Cancer Institute, Oregon Health Science University, Portland; ⁵Medical Oncology, Thomas Jefferson University, Philadelphia; ⁶Investigational Drug Branch, Division of Cancer Treatment and Diagnosis; ⁷Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda; ⁸Department of Biostatistics, Dana Farber Cancer Institutes, Boston; ⁹Biometric Research Branch, National Cancer Institute, Bethesda; ¹⁰Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health, Bethesda; ¹¹Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda; ¹²Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick; ¹³Department of Pathology, University of Texas MD Anderson Cancer Center, Houston; ¹⁴Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda; ¹⁵Department of Internal Medicine, University of Texas Southwestern, Dallas; ¹⁶University of Pennsylvania, Philadelphia; ¹⁷CTEP, National Cancer Institute, Bethesda; ¹⁸Cancer Center, Massachusetts General Hospital, Boston, USA

The authors regret that Dr Arteaga’s disclosures were not complete in the original publication. Dr Arteaga’s full disclosure should read as follows:

CLA: grant support: Pfizer, Lilly, Radius, PUMA Biotechnology, Bayer, Takeda, Symphogen; honoraria: advisory board/steering committee: Daiichi Sankyo, ABBVIE, Novartis, Lilly, Sanofi, Radius, Taiho Oncology, PUMA Biotechnology, Merck, H3Biomedicine, Symphogen, OrigiMed, Immunomedics, Petra Pharma, G1 Therapeutics, Athenex, Dr Arteaga receives compensation for his role in the Scientific Advisory Board of the Komen Foundation, unrelated to this work; stock options: Provista, Y-TRAP. LNH: patents, royalties, other intellectual property—Philips Healthcare.

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1093/annonc/mdz291>

*Correspondence to: Dr. Komal L. Jhaveri, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Tel:+1-646-888-5145; Fax:+1-646-888-4917

E-mail: jhaverik@mskcc.org (K. L. Jhaveri).

0923-7534/© 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).